Pharmacotherapy for pain in a family with inherited erythromelalgia guided by genomic analysis and functional profiling

JAMA Neurology

Volumn 73, Issue 6, 2016, Pages 659-667

  Geha, Paul ^a,b   Yang, Yang ^a,c   Estacion, Mark ^a,c   Schulman, Betsy R ^a,c   Tokuno, Hajime ^a   Apkarian, A Vania ^d   Dib Hajj, Sulayman D ^a   Waxman, Stephen G ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHN B PIERCE LABORATORY   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; PLACEBO; SODIUM CHANNEL NAV1.7; ANALGESIC AGENT; SCN9A PROTEIN, HUMAN;

ADULT; ARTICLE; CASE REPORT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROMELALGIA; FIRING RATE; FUNCTIONAL GENOMICS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL PROFILING; GENOME ANALYSIS; HUMAN; INHERITED ERYTHROMELALGIA; MOLECULAR MODEL; PAIN; PAIN ASSESSMENT; PAIN INTENSITY; PRIMARY SOMATOSENSORY CORTEX; PRIORITY JOURNAL; SECONDARY SOMATOSENSORY CORTEX; SPINAL CORD NERVE CELL; SPINAL GANGLION; THERMODYNAMICS; ACTION POTENTIAL; BRAIN; CHRONIC PAIN; COMPLICATION; CYTOLOGY; DIAGNOSTIC IMAGING; DNA MUTATIONAL ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ELECTROSTIMULATION; FEMALE; GENETICS; MALE; METABOLISM; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN MEASUREMENT; REGRESSION ANALYSIS; SENSORY NERVE CELL;

ACTION POTENTIALS; ADULT; ANALGESICS, NON-NARCOTIC; BRAIN; CARBAMAZEPINE; CHRONIC PAIN; DNA MUTATIONAL ANALYSIS; DOUBLE-BLIND METHOD; ELECTRIC STIMULATION; ERYTHROMELALGIA; FEMALE; GANGLIA, SPINAL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MUTATION; NAV1.7 VOLTAGE-GATED SODIUM CHANNEL; PAIN MEASUREMENT; REGRESSION ANALYSIS; SENSORY RECEPTOR CELLS;

EID: 84974604641     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.0389     Document Type: Article

References (33)

1. Drenth JP,Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest. 2007; 117(12):3603-3609.
2. Dib-Hajj SD, Yang Y, Black JA,Waxman SG. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2013;14(1):49-62.
3. Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA,Waxman SG. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl Acad Sci U S A. 2006; 103(21):8245-8250.
4. Toledo-Aral JJ, Moss BL, He ZJ, et al. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc Natl Acad Sci U S A. 1997;94(4):1527-1532.
5. Fischer TZ, Gilmore ES, Estacion M, et al. A novel Nav1.7 mutation producing carbamazepineresponsive erythromelalgia. Ann Neurol. 2009;65 (6):733-741.
6. Yang Y, Dib-Hajj SD, Zhang J, et al. Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Na(V)1.7 mutant channel. Nat Commun. 2012;3:1186.
7. Baliki MN, Chialvo DR, Geha PY, et al. Chronic pain and the emotional brain: specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. J Neurosci. 2006;26 (47):12165-12173.
8. Baliki MN, Geha PY, Fields HL, Apkarian AV. Predicting value of pain and analgesia: nucleus accumbens response to noxious stimuli changes in the presence of chronic pain. Neuron. 2010;66(1): 149-160.
9. Baliki MN, Petre B, Torbey S, et al. Corticostriatal functional connectivity predicts transition to chronic back pain. Nat Neurosci. 2012;15(8):1117-1119.
10. Ellingsen DM,Wessberg J, Eikemo M, et al. Placebo improves pleasure and pain through opposite modulation of sensory processing. Proc Natl Acad Sci U S A. 2013;110(44):17993-17998.
11. Geha PY, Baliki MN, Chialvo DR, Harden RN, Paice JA, Apkarian AV. Brain activity for spontaneous pain of postherpetic neuralgia and its modulation by lidocaine patch therapy. Pain. 2007; 128(1-2):88-100.
12. Geha PY, Baliki MN, Harden RN, Bauer WR, Parrish TB, Apkarian AV. The brain in chronic CRPS pain: abnormal gray-white matter interactions in emotional and autonomic regions. Neuron. 2008; 60(4):570-581.
13. Hashmi JA, Baliki MN, Huang L, et al. Shape shifting pain: chronification of back pain shifts brain representation from nociceptive to emotional circuits. Brain. 2013;136(pt 9):2751-2768.
14. Kable JW, Glimcher PW. The neural correlates of subjective value during intertemporal choice. Nat Neurosci. 2007;10(12):1625-1633.
15. Foss JM, Apkarian AV, Chialvo DR. Dynamics of pain: fractal dimension of temporal variability of spontaneous pain differentiates between pain States. J Neurophysiol. 2006;95(2):730-736.
16. Levy DJ, Glimcher PW. The root of all value: a neural common currency for choice. Curr Opin Neurobiol. 2012;22(6):1027-1038.
17. Eickhoff SB, Stephan KE, Mohlberg H, et al. A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. Neuroimage. 2005;25(4):1325-1335.
18. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. 2005;9(4):463-484.
19. Qiao X, Sun G, Clare JJ,Werkman TR,Wadman WJ. Properties of human brain sodium channel a-subunits expressed in HEK293 cells and their modulation by carbamazepine, phenytoin and lamotrigine. Br J Pharmacol. 2014;171(4):1054-1067.
20. Jo S, Bean BP. Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014;85(2):381-387.
21. Jokeit H, OkujavaM,Woermann FG. Carbamazepine reduces memory induced activation ofmesial temporal lobe structures: a pharmacological fMRI-study. BMC Neurol. 2001;1: 6.
22. Dib-Hajj SD, Rush AM, Cummins TR, et al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain. 2005;128(pt 8):1847-1854.
23. Lamm C, Decety J, Singer T. Meta-analytic evidence for common and distinct neural networks associated with directly experienced pain and empathy for pain. Neuroimage. 2011;54(3):2492-2502.
24. Diederich NJ, Goetz CG. The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology. 2008;71(9):677-684.
25. Hashmi JA, Baria AT, Baliki MN, Huang L, Schnitzer TJ, Apkarian AV. Brain networks predicting placebo analgesia in a clinical trial for chronic back pain. Pain. 2012;153(12):2393-2402.
26. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med. 2010;16(11):1277-1283.
27. Wager TD, Rilling JK, Smith EE, et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science. 2004; 303(5661):1162-1167.
28. Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci. 2009;1156:198-210.
29. Seymour B, O'Doherty JP, Koltzenburg M, et al. Opponent appetitive-aversive neural processes underlie predictive learning of pain relief. Nat Neurosci. 2005;8(9):1234-1240.
30. Mesulam MM. From sensation to cognition. Brain. 1998;121(pt 6):1013-1052.
31. CorbettaM, Shulman GL. Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci. 2002;3(3):201-215.
32. Segerdahl AR, Xie J, Paterson K, Ramirez JD, Tracey I, Bennett DL. Imaging the neural correlates of neuropathic pain and pleasurable relief associated with inherited erythromelalgia in a single subject with quantitative arterial spin labelling. Pain. 2012;153(5):1122-1127.
33. Waxman SG, Merkies IS, Gerrits MM, et al. Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use. Lancet Neurol. 2014;13(11):1152-1160.